nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—Henoch-Schonlein purpura—Hydrochlorothiazide—nephrolithiasis	0.0257	0.0804	CcSEcCtD
L-DOPA—Shoulder pain—Hydrochlorothiazide—nephrolithiasis	0.0216	0.0678	CcSEcCtD
L-DOPA—SLC7A8—Amino acid transport across the plasma membrane—SLC7A9—nephrolithiasis	0.0134	0.0247	CbGpPWpGaD
L-DOPA—SLC7A5—Amino acid and oligopeptide SLC transporters—SLC3A1—nephrolithiasis	0.0129	0.0238	CbGpPWpGaD
L-DOPA—Leg pain—Hydrochlorothiazide—nephrolithiasis	0.0126	0.0395	CcSEcCtD
L-DOPA—PSIP1—nephron tubule—nephrolithiasis	0.0125	0.0916	CbGeAlD
L-DOPA—SLC16A10—Amino acid transport across the plasma membrane—SLC3A1—nephrolithiasis	0.0124	0.0228	CbGpPWpGaD
L-DOPA—SLC7A5—Amino acid transport across the plasma membrane—SLC7A9—nephrolithiasis	0.0117	0.0216	CbGpPWpGaD
L-DOPA—PSIP1—renal system—nephrolithiasis	0.0114	0.0833	CbGeAlD
L-DOPA—PSIP1—cortex of kidney—nephrolithiasis	0.0107	0.0784	CbGeAlD
L-DOPA—SLC7A8—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A6—nephrolithiasis	0.00955	0.0176	CbGpPWpGaD
L-DOPA—Serum creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00948	0.0297	CcSEcCtD
L-DOPA—SLC7A8—Amino acid and oligopeptide SLC transporters—SLC7A9—nephrolithiasis	0.00932	0.0171	CbGpPWpGaD
L-DOPA—SLC7A8—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A3—nephrolithiasis	0.00874	0.0161	CbGpPWpGaD
L-DOPA—SLC7A8—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC3A1—nephrolithiasis	0.00874	0.0161	CbGpPWpGaD
L-DOPA—SLC16A10—Amino acid and oligopeptide SLC transporters—SLC3A1—nephrolithiasis	0.0086	0.0158	CbGpPWpGaD
L-DOPA—Heartburn—Hydrochlorothiazide—nephrolithiasis	0.00847	0.0265	CcSEcCtD
L-DOPA—SLC7A5—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A6—nephrolithiasis	0.00834	0.0153	CbGpPWpGaD
L-DOPA—SLC7A8—nephron tubule—nephrolithiasis	0.00826	0.0604	CbGeAlD
L-DOPA—SLC7A5—Amino acid and oligopeptide SLC transporters—SLC7A9—nephrolithiasis	0.00813	0.015	CbGpPWpGaD
L-DOPA—SLC16A10—Amino acid transport across the plasma membrane—SLC7A9—nephrolithiasis	0.00779	0.0143	CbGpPWpGaD
L-DOPA—SLC7A5—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A3—nephrolithiasis	0.00762	0.014	CbGpPWpGaD
L-DOPA—SLC7A5—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC3A1—nephrolithiasis	0.00762	0.014	CbGpPWpGaD
L-DOPA—SLC7A8—renal system—nephrolithiasis	0.00751	0.0549	CbGeAlD
L-DOPA—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.00743	0.0232	CcSEcCtD
L-DOPA—SLC7A8—kidney—nephrolithiasis	0.00726	0.053	CbGeAlD
L-DOPA—DDC—nephron tubule—nephrolithiasis	0.00714	0.0522	CbGeAlD
L-DOPA—SLC7A8—cortex of kidney—nephrolithiasis	0.00707	0.0517	CbGeAlD
L-DOPA—Numbness—Hydrochlorothiazide—nephrolithiasis	0.00703	0.022	CcSEcCtD
L-DOPA—CYP2D6—urine—nephrolithiasis	0.00692	0.0506	CbGeAlD
L-DOPA—Sensory loss—Hydrochlorothiazide—nephrolithiasis	0.00673	0.0211	CcSEcCtD
L-DOPA—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC3A1—nephrolithiasis	0.00668	0.0123	CbGpPWpGaD
L-DOPA—SLC7A8—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A1—nephrolithiasis	0.00662	0.0122	CbGpPWpGaD
L-DOPA—DDC—renal system—nephrolithiasis	0.00649	0.0475	CbGeAlD
L-DOPA—SLC7A5—nephron tubule—nephrolithiasis	0.0064	0.0468	CbGeAlD
L-DOPA—DDC—kidney—nephrolithiasis	0.00628	0.0459	CbGeAlD
L-DOPA—SLC7A8—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A1—nephrolithiasis	0.00616	0.0113	CbGpPWpGaD
L-DOPA—DDC—cortex of kidney—nephrolithiasis	0.00611	0.0447	CbGeAlD
L-DOPA—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.0059	0.0185	CcSEcCtD
L-DOPA—SLC7A5—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A1—nephrolithiasis	0.00578	0.0106	CbGpPWpGaD
L-DOPA—SLC16A10—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A6—nephrolithiasis	0.00554	0.0102	CbGpPWpGaD
L-DOPA—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.0055	0.0172	CcSEcCtD
L-DOPA—SLC7A8—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A9—nephrolithiasis	0.00549	0.0101	CbGpPWpGaD
L-DOPA—SLC7A5—cortex of kidney—nephrolithiasis	0.00548	0.04	CbGeAlD
L-DOPA—SLC16A10—Amino acid and oligopeptide SLC transporters—SLC7A9—nephrolithiasis	0.0054	0.00994	CbGpPWpGaD
L-DOPA—SLC7A5—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A1—nephrolithiasis	0.00537	0.00988	CbGpPWpGaD
L-DOPA—SLC15A1—nephron tubule—nephrolithiasis	0.00531	0.0388	CbGeAlD
L-DOPA—SLC7A8—Cell surface interactions at the vascular wall—SLC7A9—nephrolithiasis	0.00531	0.00977	CbGpPWpGaD
L-DOPA—SLC16A10—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC3A1—nephrolithiasis	0.00507	0.00932	CbGpPWpGaD
L-DOPA—SLC16A10—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A3—nephrolithiasis	0.00507	0.00932	CbGpPWpGaD
L-DOPA—SLC16A10—nephron tubule—nephrolithiasis	0.0049	0.0358	CbGeAlD
L-DOPA—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00489	0.0153	CcSEcCtD
L-DOPA—SLC15A1—renal system—nephrolithiasis	0.00483	0.0353	CbGeAlD
L-DOPA—SLC7A5—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A9—nephrolithiasis	0.00479	0.00881	CbGpPWpGaD
L-DOPA—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.00473	0.0148	CcSEcCtD
L-DOPA—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00469	0.0147	CcSEcCtD
L-DOPA—SLC15A1—kidney—nephrolithiasis	0.00467	0.0341	CbGeAlD
L-DOPA—SLC7A5—Cell surface interactions at the vascular wall—SLC7A9—nephrolithiasis	0.00463	0.00852	CbGpPWpGaD
L-DOPA—DRD5—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00453	0.00834	CbGpPWpGaD
L-DOPA—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.00452	0.0142	CcSEcCtD
L-DOPA—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00449	0.014	CcSEcCtD
L-DOPA—Purpura—Hydrochlorothiazide—nephrolithiasis	0.00439	0.0137	CcSEcCtD
L-DOPA—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A6—nephrolithiasis	0.0043	0.00792	CbGpPWpGaD
L-DOPA—SLC7A8—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00427	0.00785	CbGpPWpGaD
L-DOPA—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00423	0.0132	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00423	0.0132	CcSEcCtD
L-DOPA—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.0042	0.0131	CcSEcCtD
L-DOPA—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC7A9—nephrolithiasis	0.0042	0.00772	CbGpPWpGaD
L-DOPA—SLC16A10—cortex of kidney—nephrolithiasis	0.00419	0.0307	CbGeAlD
L-DOPA—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.00398	0.0125	CcSEcCtD
L-DOPA—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00397	0.0124	CcSEcCtD
L-DOPA—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A3—nephrolithiasis	0.00394	0.00724	CbGpPWpGaD
L-DOPA—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC3A1—nephrolithiasis	0.00394	0.00724	CbGpPWpGaD
L-DOPA—SLC7A8—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00391	0.00718	CbGpPWpGaD
L-DOPA—SLC7A8—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00391	0.00718	CbGpPWpGaD
L-DOPA—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00387	0.0121	CcSEcCtD
L-DOPA—SLC16A10—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A1—nephrolithiasis	0.00384	0.00706	CbGpPWpGaD
L-DOPA—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00381	0.0119	CcSEcCtD
L-DOPA—DRD5—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00381	0.00701	CbGpPWpGaD
L-DOPA—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.00375	0.0117	CcSEcCtD
L-DOPA—SLC7A5—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00373	0.00685	CbGpPWpGaD
L-DOPA—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00366	0.0114	CcSEcCtD
L-DOPA—SLC16A10—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A1—nephrolithiasis	0.00357	0.00657	CbGpPWpGaD
L-DOPA—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00356	0.0112	CcSEcCtD
L-DOPA—SLC7A5—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00341	0.00627	CbGpPWpGaD
L-DOPA—SLC7A5—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00341	0.00627	CbGpPWpGaD
L-DOPA—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.0034	0.0106	CcSEcCtD
L-DOPA—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00338	0.0106	CcSEcCtD
L-DOPA—DRD4—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00335	0.00615	CbGpPWpGaD
L-DOPA—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.00333	0.0104	CcSEcCtD
L-DOPA—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00322	0.0101	CcSEcCtD
L-DOPA—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.0032	0.01	CcSEcCtD
L-DOPA—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.0032	0.01	CcSEcCtD
L-DOPA—SLC16A10—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A9—nephrolithiasis	0.00318	0.00585	CbGpPWpGaD
L-DOPA—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00317	0.00992	CcSEcCtD
L-DOPA—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00304	0.00953	CcSEcCtD
L-DOPA—DRD1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00301	0.00554	CbGpPWpGaD
L-DOPA—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A1—nephrolithiasis	0.00298	0.00549	CbGpPWpGaD
L-DOPA—DRD3—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00297	0.00547	CbGpPWpGaD
L-DOPA—SLC7A8—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00296	0.00544	CbGpPWpGaD
L-DOPA—SLC7A8—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00296	0.00544	CbGpPWpGaD
L-DOPA—DDC—Amino acid and derivative metabolism—GRHPR—nephrolithiasis	0.00294	0.0054	CbGpPWpGaD
L-DOPA—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00294	0.00919	CcSEcCtD
L-DOPA—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00291	0.00912	CcSEcCtD
L-DOPA—DRD4—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00281	0.00517	CbGpPWpGaD
L-DOPA—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A1—nephrolithiasis	0.00277	0.0051	CbGpPWpGaD
L-DOPA—SLC7A8—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00275	0.00506	CbGpPWpGaD
L-DOPA—SLC7A8—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00275	0.00506	CbGpPWpGaD
L-DOPA—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00272	0.0085	CcSEcCtD
L-DOPA—DDC—Amino acid and derivative metabolism—AGXT—nephrolithiasis	0.00262	0.00481	CbGpPWpGaD
L-DOPA—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00262	0.00819	CcSEcCtD
L-DOPA—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00259	0.0081	CcSEcCtD
L-DOPA—SLC7A5—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00258	0.00475	CbGpPWpGaD
L-DOPA—SLC7A5—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00258	0.00475	CbGpPWpGaD
L-DOPA—DRD1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00253	0.00466	CbGpPWpGaD
L-DOPA—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00251	0.00786	CcSEcCtD
L-DOPA—Tension—Hydrochlorothiazide—nephrolithiasis	0.0025	0.00783	CcSEcCtD
L-DOPA—DRD3—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0025	0.00459	CbGpPWpGaD
L-DOPA—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.0025	0.00781	CcSEcCtD
L-DOPA—SLC16A10—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00248	0.00455	CbGpPWpGaD
L-DOPA—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00248	0.00775	CcSEcCtD
L-DOPA—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A9—nephrolithiasis	0.00247	0.00455	CbGpPWpGaD
L-DOPA—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00247	0.00772	CcSEcCtD
L-DOPA—SLC7A8—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00245	0.00451	CbGpPWpGaD
L-DOPA—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00245	0.00767	CcSEcCtD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00243	0.00448	CbGpPWpGaD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00243	0.00448	CbGpPWpGaD
L-DOPA—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.0024	0.00752	CcSEcCtD
L-DOPA—SLC7A5—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.0024	0.00442	CbGpPWpGaD
L-DOPA—SLC7A5—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.0024	0.00442	CbGpPWpGaD
L-DOPA—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00239	0.00747	CcSEcCtD
L-DOPA—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00236	0.0074	CcSEcCtD
L-DOPA—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00236	0.00737	CcSEcCtD
L-DOPA—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00234	0.00733	CcSEcCtD
L-DOPA—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00233	0.00729	CcSEcCtD
L-DOPA—Malaise—Hydrochlorothiazide—nephrolithiasis	0.0023	0.00719	CcSEcCtD
L-DOPA—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00229	0.00715	CcSEcCtD
L-DOPA—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00228	0.00714	CcSEcCtD
L-DOPA—DRD2—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00227	0.00418	CbGpPWpGaD
L-DOPA—SLC16A10—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00226	0.00416	CbGpPWpGaD
L-DOPA—SLC16A10—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00226	0.00416	CbGpPWpGaD
L-DOPA—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00225	0.00705	CcSEcCtD
L-DOPA—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00224	0.00701	CcSEcCtD
L-DOPA—Cough—Hydrochlorothiazide—nephrolithiasis	0.00222	0.00696	CcSEcCtD
L-DOPA—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00217	0.00679	CcSEcCtD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00217	0.00399	CbGpPWpGaD
L-DOPA—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00216	0.00677	CcSEcCtD
L-DOPA—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00214	0.00671	CcSEcCtD
L-DOPA—SLC7A5—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00214	0.00394	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00212	0.00391	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00212	0.00391	CbGpPWpGaD
L-DOPA—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00212	0.00664	CcSEcCtD
L-DOPA—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.0021	0.00656	CcSEcCtD
L-DOPA—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00208	0.00651	CcSEcCtD
L-DOPA—Shock—Hydrochlorothiazide—nephrolithiasis	0.00205	0.00641	CcSEcCtD
L-DOPA—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00204	0.00637	CcSEcCtD
L-DOPA—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00201	0.00629	CcSEcCtD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00198	0.00365	CbGpPWpGaD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00198	0.00365	CbGpPWpGaD
L-DOPA—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00198	0.00621	CcSEcCtD
L-DOPA—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00194	0.00608	CcSEcCtD
L-DOPA—SLC15A1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00192	0.00354	CbGpPWpGaD
L-DOPA—DRD2—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00191	0.00352	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00189	0.00348	CbGpPWpGaD
L-DOPA—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00188	0.00589	CcSEcCtD
L-DOPA—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00187	0.00585	CcSEcCtD
L-DOPA—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00185	0.0058	CcSEcCtD
L-DOPA—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00185	0.00579	CcSEcCtD
L-DOPA—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00183	0.00573	CcSEcCtD
L-DOPA—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00181	0.00566	CcSEcCtD
L-DOPA—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00179	0.00561	CcSEcCtD
L-DOPA—Pain—Hydrochlorothiazide—nephrolithiasis	0.00178	0.00557	CcSEcCtD
L-DOPA—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00178	0.00557	CcSEcCtD
L-DOPA—SLC15A1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00176	0.00324	CbGpPWpGaD
L-DOPA—SLC15A1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00176	0.00324	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00173	0.00318	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00173	0.00318	CbGpPWpGaD
L-DOPA—SLC16A10—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00172	0.00316	CbGpPWpGaD
L-DOPA—SLC16A10—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00172	0.00316	CbGpPWpGaD
L-DOPA—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00171	0.00536	CcSEcCtD
L-DOPA—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.0017	0.00532	CcSEcCtD
L-DOPA—CYP2D6—renal system—nephrolithiasis	0.00169	0.0124	CbGeAlD
L-DOPA—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00165	0.00517	CcSEcCtD
L-DOPA—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00164	0.00515	CcSEcCtD
L-DOPA—CYP2D6—kidney—nephrolithiasis	0.00164	0.012	CbGeAlD
L-DOPA—SLC16A10—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.0016	0.00293	CbGpPWpGaD
L-DOPA—SLC16A10—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.0016	0.00293	CbGpPWpGaD
L-DOPA—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00153	0.0048	CcSEcCtD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.0015	0.00277	CbGpPWpGaD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.0015	0.00277	CbGpPWpGaD
L-DOPA—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00149	0.00467	CcSEcCtD
L-DOPA—DRD4—GPCRs, Other—CHRM3—nephrolithiasis	0.00149	0.00273	CbGpPWpGaD
L-DOPA—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00147	0.00461	CcSEcCtD
L-DOPA—SLC7A8—Hemostasis—DGKH—nephrolithiasis	0.00144	0.00265	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—SLC7A9—nephrolithiasis	0.00144	0.00265	CbGpPWpGaD
L-DOPA—DRD5—G alpha (s) signalling events—PTH—nephrolithiasis	0.00144	0.00264	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00142	0.00262	CbGpPWpGaD
L-DOPA—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00142	0.00445	CcSEcCtD
L-DOPA—SLC16A10—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00142	0.00262	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00141	0.0026	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00141	0.0026	CbGpPWpGaD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.0014	0.00257	CbGpPWpGaD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.0014	0.00257	CbGpPWpGaD
L-DOPA—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00138	0.00431	CcSEcCtD
L-DOPA—SLC15A1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00133	0.00245	CbGpPWpGaD
L-DOPA—SLC15A1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00133	0.00245	CbGpPWpGaD
L-DOPA—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00132	0.00414	CcSEcCtD
L-DOPA—DRD3—GPCRs, Other—CHRM3—nephrolithiasis	0.00132	0.00243	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00131	0.00241	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00131	0.00241	CbGpPWpGaD
L-DOPA—Rash—Hydrochlorothiazide—nephrolithiasis	0.00131	0.0041	CcSEcCtD
L-DOPA—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00131	0.0041	CcSEcCtD
L-DOPA—Headache—Hydrochlorothiazide—nephrolithiasis	0.0013	0.00408	CcSEcCtD
L-DOPA—DRD3—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00127	0.00233	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00126	0.00231	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—SLC7A9—nephrolithiasis	0.00126	0.00231	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—DGKH—nephrolithiasis	0.00126	0.00231	CbGpPWpGaD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00125	0.00229	CbGpPWpGaD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00125	0.00229	CbGpPWpGaD
L-DOPA—SLC15A1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00124	0.00228	CbGpPWpGaD
L-DOPA—SLC15A1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00124	0.00228	CbGpPWpGaD
L-DOPA—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00124	0.00387	CcSEcCtD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00122	0.00224	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00122	0.00224	CbGpPWpGaD
L-DOPA—PSIP1—Disease—SLC26A1—nephrolithiasis	0.0012	0.0022	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00115	0.00212	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00115	0.00212	CbGpPWpGaD
L-DOPA—SLC15A1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.0011	0.00203	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.0011	0.00202	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.0011	0.00202	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00109	0.002	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00109	0.002	CbGpPWpGaD
L-DOPA—PSIP1—Disease—ATP6V0A4—nephrolithiasis	0.00107	0.00196	CbGpPWpGaD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000996	0.00183	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000977	0.0018	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000968	0.00178	CbGpPWpGaD
L-DOPA—DRD1—G alpha (s) signalling events—PTH—nephrolithiasis	0.000955	0.00176	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000894	0.00164	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000894	0.00164	CbGpPWpGaD
L-DOPA—DRD5—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000875	0.00161	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000872	0.0016	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000872	0.0016	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000869	0.0016	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000811	0.00149	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000811	0.00149	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00075	0.00138	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000723	0.00133	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000723	0.00133	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000677	0.00125	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000677	0.00125	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—RGS14—nephrolithiasis	0.00066	0.00121	CbGpPWpGaD
L-DOPA—DRD4—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000646	0.00119	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00063	0.00116	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00063	0.00116	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—RGS14—nephrolithiasis	0.0006	0.0011	CbGpPWpGaD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000581	0.00107	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000578	0.00106	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000574	0.00105	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—CHRM3—nephrolithiasis	0.000571	0.00105	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000561	0.00103	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000561	0.00103	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000553	0.00102	CbGpPWpGaD
L-DOPA—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.000549	0.00101	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GRHPR—nephrolithiasis	0.000539	0.000992	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—PTH—nephrolithiasis	0.000522	0.00096	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000498	0.000916	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000491	0.000904	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—RGS14—nephrolithiasis	0.000487	0.000897	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AGXT—nephrolithiasis	0.000481	0.000884	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000449	0.000825	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—DGKH—nephrolithiasis	0.000446	0.000821	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—RGS14—nephrolithiasis	0.000443	0.000814	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000439	0.000807	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—RGS14—nephrolithiasis	0.000439	0.000807	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—RGS14—nephrolithiasis	0.000433	0.000796	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CHRM3—nephrolithiasis	0.000421	0.000775	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ADCY10—nephrolithiasis	0.000417	0.000766	CbGpPWpGaD
L-DOPA—DDC—Metabolism—SLC26A1—nephrolithiasis	0.000409	0.000752	CbGpPWpGaD
L-DOPA—DDC—Metabolism—APRT—nephrolithiasis	0.000409	0.000752	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—DGKH—nephrolithiasis	0.000405	0.000745	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—RGS14—nephrolithiasis	0.000399	0.000733	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—RGS14—nephrolithiasis	0.000393	0.000723	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—PTH—nephrolithiasis	0.000385	0.000709	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CHRM3—nephrolithiasis	0.000379	0.000698	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000376	0.000692	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CHRM3—nephrolithiasis	0.000374	0.000688	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RGS14—nephrolithiasis	0.000354	0.000652	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—PTH—nephrolithiasis	0.000347	0.000638	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—PTH—nephrolithiasis	0.000342	0.000629	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—RGS14—nephrolithiasis	0.000331	0.000609	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—DGKH—nephrolithiasis	0.000329	0.000606	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000323	0.000593	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ADCY10—nephrolithiasis	0.000308	0.000566	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—RGS14—nephrolithiasis	0.000301	0.000553	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—DGKH—nephrolithiasis	0.000299	0.00055	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—DGKH—nephrolithiasis	0.000296	0.000545	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—PTH—nephrolithiasis	0.000295	0.000543	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CHRM3—nephrolithiasis	0.000293	0.000539	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—DGKH—nephrolithiasis	0.000292	0.000538	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AQP1—nephrolithiasis	0.000291	0.000536	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CHRM3—nephrolithiasis	0.000286	0.000527	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ADCY10—nephrolithiasis	0.000277	0.000509	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ADCY10—nephrolithiasis	0.000273	0.000502	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—DGKH—nephrolithiasis	0.000269	0.000495	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PTH—nephrolithiasis	0.000268	0.000493	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—DGKH—nephrolithiasis	0.000266	0.000489	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CHRM3—nephrolithiasis	0.000263	0.000484	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—PTH—nephrolithiasis	0.000262	0.000482	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RGS14—nephrolithiasis	0.000262	0.000481	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000239	0.00044	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—DGKH—nephrolithiasis	0.000239	0.00044	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000238	0.000438	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RGS14—nephrolithiasis	0.000235	0.000433	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RGS14—nephrolithiasis	0.000232	0.000427	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—DGKH—nephrolithiasis	0.000224	0.000412	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PTH—nephrolithiasis	0.000218	0.0004	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CHRM3—nephrolithiasis	0.000216	0.000398	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000214	0.000394	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000211	0.000389	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ADCY10—nephrolithiasis	0.000209	0.000384	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—DGKH—nephrolithiasis	0.000203	0.000374	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PTH—nephrolithiasis	0.000198	0.000364	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PTH—nephrolithiasis	0.000196	0.000361	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CHRM3—nephrolithiasis	0.000195	0.000358	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PTH—nephrolithiasis	0.000193	0.000356	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CHRM3—nephrolithiasis	0.000192	0.000353	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PTH—nephrolithiasis	0.000178	0.000327	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RGS14—nephrolithiasis	0.000178	0.000327	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—DGKH—nephrolithiasis	0.000177	0.000325	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000177	0.000325	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PTH—nephrolithiasis	0.000176	0.000323	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CHRM3—nephrolithiasis	0.000173	0.000318	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000162	0.000298	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000159	0.000292	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—DGKH—nephrolithiasis	0.000159	0.000292	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTH—nephrolithiasis	0.000158	0.000291	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—DGKH—nephrolithiasis	0.000157	0.000289	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000157	0.000289	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PTH—nephrolithiasis	0.000148	0.000272	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CHRM3—nephrolithiasis	0.000147	0.00027	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PTH—nephrolithiasis	0.000134	0.000247	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CHRM3—nephrolithiasis	0.000128	0.000235	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000124	0.000228	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—DGKH—nephrolithiasis	0.00012	0.000221	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00012	0.000221	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTH—nephrolithiasis	0.000117	0.000215	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CHRM3—nephrolithiasis	0.000115	0.000211	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CHRM3—nephrolithiasis	0.000113	0.000209	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000111	0.000203	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTH—nephrolithiasis	0.000105	0.000193	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTH—nephrolithiasis	0.000104	0.000191	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	9.4e-05	0.000173	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APRT—nephrolithiasis	9.4e-05	0.000173	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CHRM3—nephrolithiasis	8.68e-05	0.00016	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SPP1—nephrolithiasis	7.95e-05	0.000146	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTH—nephrolithiasis	7.94e-05	0.000146	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AQP1—nephrolithiasis	6.7e-05	0.000123	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CHRM3—nephrolithiasis	6.06e-05	0.000111	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SPP1—nephrolithiasis	5.86e-05	0.000108	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SPP1—nephrolithiasis	5.28e-05	9.71e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SPP1—nephrolithiasis	5.21e-05	9.58e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SPP1—nephrolithiasis	3.99e-05	7.33e-05	CbGpPWpGaD
